• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Nutraceuticals for Men: Muscle Health and Performance Nutrition

    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions

    Getting an Edge in Esports: Meeting the Health Needs of Competitive Gamers

    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

    Leveling Out the Energy Segment for Mainstream, and Rethinking Caffeine
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada

    Coca-Cola to Phase Out Honest Tea Brand by Year’s End, Citing Supply Chain Challenges

    Vitafoods Europe 2022 Attendance Returns to 2019 Level

    Beyond Raw Launches Concept X Pre-Workout Line
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Botanical Ingredient MorActive Evidenced to Relieve Back Discomfort

    Cargill’s Stevia Sustainability Program Benchmarked by FSA

    GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe

    Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada

    Coca-Cola to Phase Out Honest Tea Brand by Year’s End, Citing Supply Chain Challenges

    Vitafoods Europe 2022 Attendance Returns to 2019 Level

    Beyond Raw Launches Concept X Pre-Workout Line
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Beyond Raw Launches Concept X Pre-Workout Line

    Botanical Ingredient MorActive Evidenced to Relieve Back Discomfort

    Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board

    Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Verdure Sciences

    Applied Food Sciences, Inc.

    Aiya America, Inc. (Aiya Matcha)

    Xsto Solutions

    ESHA Research
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Verdure Sciences

    Applied Food Sciences, Inc.

    Aiya America, Inc. (Aiya Matcha)

    Xsto Solutions

    ESHA Research
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Blog

    FDA ‘Chills’ Cannabidiol Marketplace

    Agency sent a series of warning letters to companies marketing dietary supplements containing CBD oil on Feb. 9.

    FDA ‘Chills’ Cannabidiol Marketplace
    Government actions have sparked a legal argument about CBD.
    Related CONTENT
    • FDA Issues Draft Guidance on NDI Enforcement Discretion
    • Jordan Process Receives Nutrasource ICAP Certification for CBD
    • Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    • Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    • FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products
    Robert T. Hoban, Esq., Managing Partner, Hoban & Feola, LLC02.22.16
    Cannabidiol (CBD), which is one of many non-psychoactive substances contained in the plant species, Cannabis sativa L, has received a great deal of attention in recent months. CBD has entered the marketplace in many places and in many forms. Is it legal? Is it scheduled?
     
    Many botanical hemp extractors market and sell CBD in all 50 states. The legality and/or the wisdom of these practices are the subject of great debate in the cannabis industry, which encompasses both industrial/botanical hemp and the ganja/marijuana dispensary regulatory systems.
     
    Fundamentally, CBD is not specifically defined under the Federal Controlled Substances Act (CSA); it simply has not been expressly addressed under federal law. However, the DEA has taken the position that CBD is a Schedule I Controlled Substance as defined under the CSA. Without an express provision under the CSA, it is questionable whether the DEA has any sort of authority to take this position.
     
    But more importantly, in the case of Hemp Industries Association v. Drug Enforcement Association, 333 F.3d 1082 (9th Circuit. 2003), the DEA attempted to initiate rules and interpretations concerning certain cannabinoid constituents of marijuana that were not expressly set forth under the CSA or the DEA’s own regulations (at the time). The Ninth Circuit Federal Court of Appeals struck down its efforts, stating that: “[t]he petition requesting that we declare the rule to be invalid and unenforceable is GRANTED.” In short, an agency, such as the DEA, is not permitted to change a legislative rule retroactively through the process of disingenuous interpretation of the rule to mean something other than its original meaning.
     
    Nonetheless, we have seen a deliberate and wide-ranging effort on behalf of the federal government to “chill” the CBD marketplace. Perhaps this is because there is a general lack of understanding (scientific, legal and practical) on behalf of the federal government and its various relevant agencies as to CBD as a general matter. Perhaps the federal government has a real concern for CBD products intended for human consumption.
     
    FDA Action
    In May 2015, the FDA posted an online forum labeled Marijuana: Questions and Answers (this was later updated/amended in July 2015).
     
    Interestingly, this Q&A came at a time when our law firm had been able to secure a large scale national retailer for placement/sales of CBD products nationwide; this put a pause on this effort. Nonetheless, in this forum, the FDA addressed three “questions” that dealt with CBD. Importantly, the FDA addressed the following: Can products that contain cannabidiol be sold as dietary supplements?
     
    In this informal Q&A, the FDA summarily announced that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act, though questions remain whether all of the factors under that section of the FD&C Act have been satisfied to exclude CBD products from the definition of a dietary supplement.
     
    Then on Feb. 9, the FDA sent a number of warning letters to companies with dietary supplement products containing CBD oil. In all of these letters, the FDA took issue with disease claims made by the companies for the products, which is no surprise. However, of more novel interest is that in all but two of these letters, the FDA identified CBD Oil as a non-permissible dietary ingredient due to its previous investigation as a New Drug in one or more New Drug Applications. The FDA has not previously issued warning letters taking issue with CBD Oil as a dietary ingredient, although this is consistent with the FDA’s previous guidance issued as described above.
     
    State Laws
    Furthermore, this is consistent with many individual states, which have acted under their respective laws to prohibit CBD sales and/or enforce against such producers or sellers (e.g., state-based CSA provisions, unique criminal code provisions addressing cannabis constituents, or state-based medical marijuana laws or restrictive CBD-only laws). State law compliance is an issue too-often overlooked by many CBD producers/sellers, as the primary focus tends to be federal law. States have taken concerted measures to interrupt the CBD marketplace.
     
    U.S. Customs and Border Patrol
    Moreover, there has been an increase of activity concerning imported hemp material with the U.S. Customs and Border Patrol (CBP). We dealt with a spike in hemp import seizures beginning in August 2015, which has led to a number of administrative actions related thereto. Many of these seizures by the CBP were unannounced and, interestingly, no records of the confiscation could be found. These seizures mostly resulted in returning the product to its international sender and/or a finger-pointing scenario where CBP and the private carriers or customs agents would/could provide no information about the shipment’s whereabouts.
     
    Then, the seizures by CBP began to follow a normal, adopted procedure-based pattern of confiscation, where the recipient was notified by the CBP of the seizure. At first, CBP took the position that the import was an illegal dietary supplement and attempted to have the FDA exercise jurisdiction accordingly. But the FDA did not appear to take on this added responsibility and the seized shipments were able to be released.
     
    The strategy appeared to have shifted in the fall of 2015, whereby the CBP would seize the product, test for the presence of THC (without regard to amount), and attempt to have federal law enforcement exercise jurisdiction. Upon information and belief, federal law enforcement did not appear to take a more active role with the CBP.
     
    Thus, without any assistance from other agencies, the CBP acted on its own, and issued its first CBD policy statement in November 2015, which states: “[i]f the product contains tetrahydrocannabinols (THC) and causes THC to enter the human body, it is an illegal substance and may not be imported into the U.S.”
     
    Ironically, this CBP policy cites the DEA’s October 2001 policy related to industrial hemp, which was rendered void by the above-mentioned Hemp Industry Association’s case law. Before this November 2015 transition in policy, CBP’s former position (in practice) was that hemp and/or CBD products containing less than .3% THC were permissible in accordance with relevant case law. CBP has taken this position despite the fact that naturally occurring cannabinoids are not unlawful under the CSA. See: Hemp Industry Association v. DEA, 357 F.3d 1012 (9th Circuit. 2004).
     
    What Does All Of This Mean?
    None of this is surprising. And it should not be taken lightly. In fact, the best conservative practices would dictate a pause in sales and production until the issue is resolved. But the cannabis industry has always proceeded in the face of risk and adversity. That said, what does this mean for the CBD industry?
     
    Let’s start with the FDA. Its analysis as set forth in the Q&A and the Feb. 9 warning letters is incomplete and does not render this issue a “final decision” by the FDA. Instead, the law dictates, pursuant to the FD&C Act, that the conclusion it has reached can be conclusively determined only if substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. No such substantial clinical investigations have been instituted, nor made public to date. Instead, the FDA has summarily announced that these are “substantial clinical investigations.”
     
    But more importantly, the FDA duly notes that, “[t]here is an exception if the substance was ‘marketed as’ a dietary supplement or as a conventional food before the new drug investigations were authorized,” and further invites, “[i]nterested parties [to] present the agency with any evidence that they think has bearing on this issue.”
     
    This begs the question of whether CBD was marketed as a dietary supplement prior to the subject IND application. And it is important to note that following the above-referenced Q&A, the CBD industry provided substantial evidence and information indicating that CBD was, in fact, marketed and sold as a dietary supplement for many years prior to the IND application at issue.
     
    Sarah Syed, director of marketing at CV Sciences, one of the larger CBD companies in the industry stated that, “[i]t is our opinion, which is broadly shared by the marketplace, that CBD has been marketed as a dietary supplement prior to commencement and public notice of any substantial clinical investigations instituted on CBD … thereby rendering the IND preclusion inapplicable.”
     
    Importantly, a number of other dietary supplement ingredients have similarly been subject to the same scrutiny and yet continue to be sold as dietary supplements—red yeast rice, trans-resveratrol, P5P, NAC and DHEA.
     
    Thus, as a practical matter, this announcement by the FDA is premature; is part of a larger discussion; has failed to identify the date of the particular IND (and its applicants); and there is no information to suggest that the IND clinical investigations applicable here preempt the ability to market, sell and produce CBD as a dietary supplement at all. In short, while an important guidance document, the Q&A posting and corresponding position noted in the Feb. 9 warning letters, do not have the effect of a final determination on this issue.
     
    More importantly, the FDA has made no determination or assertion that CBD products are illegal or in any way run afoul of the Controlled Substances Act (CSA). As was established by the Ninth Circuit in 2004, the sale, production and distribution of CBD oils/products derived from imported raw material industrial hemp, such as those produced and sold are not in violation of the CSA (Hemp Industry Association. v. DEA, 357 F.3d 1012 (9th Cir. 2004). In fact, this case stands for the proposition that naturally occurring cannabinoids are not unlawful under the CSA.
     
    Last, under the FDA guidelines, there are a variety of categories in which a product can be placed/registered. This current FDA position addresses the category of “dietary supplements” only. It does not appear that the FDA has taken a position as to the sale or marketing of CBD products as a constituent of hemp, a food product, cosmetic product, other FDA classification, or the like.
     
    Why Is This Happening?
    Fundamentally, this is a very broad attack on the CBD industry. The FDA, FTC, CBP, and the DEA have all contributed to this “chill” in the marketplace. It is surely intentional. But what is the purpose? Is it the stigma associated with “marijuana?” Is it a fundamental lack of understanding concerning the difference between hemp and marijuana? It is probably a combination of these factors.
     
    Regardless of the reason, it would appear that this is a concerted effort to chill the CBD marketplace on all fronts. The perhaps-legitimate confusion and concern expressed by these federal and state agencies about CBD can largely be cured by an act of Congress. And the solution is the Industrial Hemp Farming Act of 2015, which amends the CSA to exclude industrial hemp from the definition of marijuana.
     
    Further, it defines “industrial hemp” to mean the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-nine tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis.
     
    Maybe these agencies simply want Congress to act? The industry certainly does. And the Industrial Hemp Farming Act of 2015 is the one-size-fits-all answer to many of these questions.
     
    In the meantime, these issues are complex and present a measurable amount of risk. It is strongly advised that you should consult with an attorney prior to marketing or distributing such products to ensure compliance with all applicable laws (including, but not limited to, FDA, FTC, CSA and applicable state laws).



    Robert T. Hoban, Esq., Managing Partner, Hoban & Feola, LLC
    * The information presented is not legal advice, and is not to be acted on as such. It is intended for informational purposes only.
     
    Bob Hoban is Managing Partner with Hoban & Feola, LLC. He is an AV Preeminent rated attorney and seasoned full-service commercial practitioner. He has more than 20 years of diverse legal and practical entrepreneurial business experience. Mr. Hoban is recognized as one of the leading commercial cannabis practitioners nationwide, representing private and publicly-held clients in numerous states and abroad. He has litigated nearly every aspect of Colorado’s Marijuana Code and has closed well-over 200 marijuana-related business transactions. Commercial marijuana and industrial hemp-based business operations, related litigation and regulatory representation are a specialty. Furthermore, Mr. Hoban is devoted to impacting law at its source; he has drafted more than 30 bills for the Colorado General Assembly in policy areas relating to eminent domain, land use, hemp/marijuana and transportation policy.
     
    Bob is also a professor at the University of Denver, in the Law and Society Program, and regularly instructs regarding government regulations, public policy advocacy and various research-based policy courses. He has completed a number of hours toward his PhD at the University of Colorado Graduate School of Public Affairs. He is a regular presenter/lecturer at legal, policy and academic conferences around the country.
    Related Searches
    • fda
    • Botanical
    • ftc
    • Dietary Supplements
    Related Knowledge Center
    • Dietary Supplements
    • Healthcare Trends
    • Regulations
    Suggested For You
    FDA Issues Draft Guidance on NDI Enforcement Discretion FDA Issues Draft Guidance on NDI Enforcement Discretion
    Jordan Process Receives Nutrasource ICAP Certification for CBD Jordan Process Receives Nutrasource ICAP Certification for CBD
    Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products
    HP Ingredients and H&AD to Showcase Ingredients at Vitafoods Europe HP Ingredients and H&AD to Showcase Ingredients at Vitafoods Europe
    James Roza of Layn Natural Ingredients: Driving the Science and Botanical Innovation James Roza of Layn Natural Ingredients: Driving the Science and Botanical Innovation
    Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing
    NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act
    Dietary Supplement Listing Bill Introduced in Senate Dietary Supplement Listing Bill Introduced in Senate
    FDA Issues NAC Enforcement Discretion Guidance FDA Issues NAC Enforcement Discretion Guidance
    Steve Mister and Tara Falsani to Co-Chair ACI/CRN Dietary Supplements Forum Steve Mister and Tara Falsani to Co-Chair ACI/CRN Dietary Supplements Forum
    FDA Seeks DSHEA Amendments FDA Seeks DSHEA Amendments
    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research Beyond CBD: Cannabis Compounds Warrant Recognition and More Research
    Wegmans to Debut Dietary Supplements Verification Program Wegmans to Debut Dietary Supplements Verification Program

    Related Content

    • Dietary Supplements | Regulations
      FDA Issues Draft Guidance on NDI Enforcement Discretion

      FDA Issues Draft Guidance on NDI Enforcement Discretion

      Amnesty for late NDI notifications is intended to encourage manufacturers and distributors to correct past failures while collecting safety data, FDA said.
      By Sean Moloughney, Editor 05.20.22

    • Breaking News | Certifications, Approvals & Patents | Herbs & Botanicals | Quality & Safety | Testing
      Jordan Process Receives Nutrasource ICAP Certification for CBD

      Jordan Process Receives Nutrasource ICAP Certification for CBD

      The company was the first raw material provider to join the certification program.
      05.18.22

    • Dietary Supplements | Regulations
      Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

      Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

      HELP Committee released discussion draft that includes language similar to Senate Bill 4090 introduced last month by Senators Durbin and Braun.
      By Sean Moloughney, Editor 05.18.22


    • Herbs & Botanicals | Quality & Safety | Testing
      Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients

      Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients

      The report concluded CBG, CBN, and CBC test articles were non-mutagenic, non-clastogenic, and non-genotoxic.
      05.06.22

    • Breaking News | Herbs & Botanicals | Industry & Market News | Quality & Safety | Regulations
      FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products

      FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products

      This marked the first time the agency took enforcement action against a delta-8 THC-containing product.
      05.04.22

      Trending
      • Oregon Files Lawsuit Against GNC | Nutraceuticals World
      • Pycnogenol Evidenced To Have Skin Benefits In Dermatology Study | Nutraceuticals World
      • Vitamin K2 Status May Impact Blood Pressure And Pulse Wave Velocity | Nutraceuticals World
      • Vitamin K2 Status May Impact Blood Pressure and Pulse Wave Velocity
      • First Day Life Shuts Down Children's Behavioral, Cognitive Health Claims Following Challenge | Nutraceuticals World
      Breaking News
      • Danone Celebrates 10th anniversary of Grant Program for Probiotics Research
      • Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada
      • Coca-Cola to Phase Out Honest Tea Brand by Year’s End, Citing Supply Chain Challenges
      • Vitafoods Europe 2022 Attendance Returns to 2019 Level
      • Beyond Raw Launches Concept X Pre-Workout Line
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Aging in Place: Lifestyle Supplements Science-Based Solutions
      • Getting an Edge in Esports: Meeting Health & Nutrition Needs
      • Nutraceuticals for Men: Muscle Health and Performance Nutrition

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada
      Coca-Cola to Phase Out Honest Tea Brand by Year’s End, Citing Supply Chain Challenges
      Vitafoods Europe 2022 Attendance Returns to 2019 Level
      Coatings World

      Latest Breaking News From Coatings World

      PPG Sets Goals to Reduce Greenhouse Gas Emissions, Unveils 2021 ESG Report
      Birla Carbon to Present Sustainable Carbon-based Solutions at PaintIndia 2022
      BTC Europe, NXTLEVVEL Biochem to Distribute Biobased & Biodegradable Solvents in Europe
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Kilo Health Invests 500,000 Euros in Pulsetto
      China to Strengthen Robotic Surgical Market With Second 5-Year Plan
      First Patient Enrolled in Alucent Biomedical's Vascular Scaffolding Clinical Trial
      Contract Pharma

      Latest Breaking News From Contract Pharma

      A Clean Sweep for AES at FOYA Awards
      Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
      INCOG BioPharma Services Opens Biomanufacturing Facility
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Men’s Skincare Market to Hit $13 Billion by End of 2022
      Estée Lauder Promotes Gibu Thomas to EVP, ELC Online
      HipDot Launches Girl Scout Cookie Collection
      Happi

      Latest Breaking News From Happi

      Duke Cannon Supply Co. Inks Five-Year Deal As Official Grooming Partner of the Army-Navy Football Game to be Held on Dec. 10
      Croda Achieves Highest Carbon Management Level in Ecovadis’ New Carbon Scorecard
      OleHenriksen’s “Big Oh Duo” Pairs New Body Skincare and Sexual Wellness Device
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Rotocon wins AI Business Excellence Award
      Quad adds Landa S10P Nanographic Printing Press
      Sihl launches materials for on-demand color label printing
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Thinx Names Meghan Davis as CEO
      Kimberly-Clark Reportedly Examining Sale of Latin American Tissue
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      James W. Stone Named AANA President
      Tom Hedman Named Senior Principal Scientist at Spinal Simplicity
      ODT's Most Read Stories This Week—May 21
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login